RET and medullary thyroid gland carcinoma: For patients with RET-mutant MTC, the advent of potent and selective RET inhibitors has led to a paradigm shift in treatment due to the highly improved risk–benefit profile with these novel agents when compared to older non-selective KIs, such as vandetanib and cabozantinib.